前立腺がん治� �剤XTANDI 中国 ….pdf

Astellas Pharma Inc. announced that the Center for Drug Evaluation of China's National Medical Products Administration has accepted its application for approval of XTANDI (enzalutamide) for the treatment of metastatic hormone-sensitive prostate cancer. The application is based on the results of the China ARCHES trial, which showed that XTANDI plus androgen deprivation therapy significantly improved the time to prostate-specific antigen progression compared to placebo plus androgen deprivation therapy. The trial results are consistent with those of the international ARCHES trial. Astellas Pharma aims to contribute to the treatment of prostate cancer by providing new treatment options. The impact of this development on the company's financial performance for the fiscal year ending March 2024 has been factored into its forecasts.